Department of Pathology, Karmanos Cancer Institute, Wayne State University, School of Medicine, 740 Hudson-Webber Cancer Research Center, 4100 John R. Street, Detroit, MI 48201, USA.
Nat Rev Gastroenterol Hepatol. 2011 Jan;8(1):27-33. doi: 10.1038/nrgastro.2010.188. Epub 2010 Nov 23.
Pancreatic cancer is a highly aggressive malignancy. This feature is believed to be partly attributable to the chemotherapy-resistant characteristics of specific subgroups of pancreatic cancer cells, namely those with an epithelial-mesenchymal transition (EMT) phenotype and cancer stem cells. Accumulating evidence suggests that several new and emerging concepts might be important in the drug-resistant phenotype of these cell types. An understanding of the molecular mechanisms underlying drug resistance in patients with pancreatic cancer might help researchers to devise novel strategies to overcome such resistance. In particular, microRNAs (miRNAs) seem to be critical regulators of drug resistance in pancreatic cancer cells. Selective and targeted elimination of cells with an EMT phenotype and cancer stem cells could be achieved by regulating the expression of specific miRNAs.
胰腺癌是一种高度侵袭性的恶性肿瘤。这种特征部分归因于特定亚群的胰腺癌细胞具有化疗耐药的特征,即具有上皮间质转化(EMT)表型和癌症干细胞的细胞。越来越多的证据表明,几种新出现的概念可能在这些细胞类型的耐药表型中很重要。对胰腺癌患者中药物耐药性的分子机制的理解可能有助于研究人员设计克服这种耐药性的新策略。特别是,microRNAs(miRNAs)似乎是胰腺癌细胞药物耐药性的关键调节因子。通过调节特定 miRNAs 的表达,可以选择性和靶向性地消除具有 EMT 表型和癌症干细胞的细胞。